For some medical conditions there are hundreds of bacteria shifts reported, for others only a few. The Percentage is based on the least number. If there are matches 8 matches for a condition that has 10 known bacteria shifts, against a condition that has 50 bacteria shifts. It will be 8/10 or 80% and not 8/50= 16%. The count of possible bacteria is shown for reference.
Limited to conditions with 5 or more bacteria
| Name | Overlap Percent | Prevalance in Population | Matches | Bacteria in From | Bacteria in To |
|---|---|---|---|---|---|
| Allergies | 24 % | 30% | 12 | 50 | 62 |
| Alzheimer's disease | 24 % | 10% | 12 | 50 | 62 |
| Autism | 32.3 % | 2% | 20 | 110 | 62 |
| Rosacea | 22.7 % | 5.46% | 5 | 22 | 62 |
| Ulcerative colitis | 40.3 % | 0.1% | 25 | 108 | 62 |
| Schizophrenia | 29 % | 0.75% | 18 | 93 | 62 |
| Ankylosing spondylitis | 43.5 % | 7% | 27 | 520 | 62 |
| Mood Disorders | 50 % | 29.7% | 3 | 6 | 62 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 38.7 % | 0.86% | 24 | 134 | 62 |
| Psoriasis | 21.7 % | 3% | 10 | 46 | 62 |
| Multiple Sclerosis | 32.3 % | 0.5% | 20 | 100 | 62 |
| Obesity | 30.6 % | 42.4% | 19 | 104 | 62 |
| Osteoporosis | 18.2 % | 9.4% | 4 | 22 | 62 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 18.6 % | 0.005% | 8 | 43 | 62 |
| neuropsychiatric disorders (PANDAS, PANS) | 46.7 % | 0.1% | 7 | 15 | 62 |
| ME/CFS without IBS | 15.4 % | 0.4% | 4 | 26 | 62 |
| Obesity | 10.9 % | 42.4% | 6 | 55 | 62 |
| Metabolic Syndrome | 42.9 % | 21% | 3 | 7 | 62 |
| ME/CFS with IBS | 31.6 % | 2.8% | 6 | 19 | 62 |
| Liver Cirrhosis | 53.2 % | 0.27% | 33 | 678 | 62 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 21 % | 25% | 13 | 76 | 62 |
| Parkinson's Disease | 25.8 % | 1% | 16 | 90 | 62 |
| Chronic Kidney Disease | 25.7 % | 15% | 9 | 35 | 62 |
| Systemic Lupus Erythematosus | 22.6 % | 0.15% | 14 | 66 | 62 |
| Depression | 27.4 % | 8% | 17 | 81 | 62 |
| IgA nephropathy (IgAN) | 31 % | 0.001% | 9 | 29 | 62 |
| Insomnia | 60 % | 30% | 6 | 10 | 62 |
| Hyperlipidemia (High Blood Fats) | 16 % | 33% | 4 | 25 | 62 |
| hypercholesterolemia (High Cholesterol) | 22.2 % | 12% | 2 | 9 | 62 |
| hypertension (High Blood Pressure | 50 % | 47% | 3 | 6 | 62 |
| Allergic Rhinitis (Hay Fever) | 11.1 % | 7.8% | 4 | 36 | 62 |
| Chronic Urticaria (Hives) | 30.4 % | 5% | 7 | 23 | 62 |
| gallstone disease (gsd) | 40 % | 5% | 6 | 15 | 62 |
| Graves' disease | 12.5 % | 0.5% | 1 | 8 | 62 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 12.5 % | 27.8% | 3 | 24 | 62 |
| Fibromyalgia | 21.6 % | 1.12% | 8 | 37 | 62 |
| Functional constipation / chronic idiopathic constipation | 26.8 % | 14% | 11 | 41 | 62 |
| Gout | 14.3 % | 6.8% | 3 | 21 | 62 |
| Epilepsy | 48 % | 0.84% | 12 | 25 | 62 |
| Cerebral Palsy | 41.2 % | 0.2% | 7 | 17 | 62 |
| Inflammatory Bowel Disease | 29 % | 1.3% | 18 | 66 | 62 |
| Type 1 Diabetes | 23.1 % | 0.19% | 12 | 52 | 62 |
| cystic fibrosis | 28.6 % | 0.03% | 2 | 7 | 62 |
| Carcinoma | 15.7 % | 1% | 8 | 51 | 62 |
| COVID-19 | 16.7 % | 50% | 6 | 36 | 62 |
| Colorectal Cancer | 30.6 % | 4.3% | 19 | 296 | 62 |
| Celiac Disease | 21 % | 1.4% | 13 | 67 | 62 |
| Chronic Fatigue Syndrome | 20 % | 3% | 11 | 55 | 62 |
| Coronary artery disease | 18.8 % | 6.7% | 3 | 16 | 62 |
| Crohn's Disease | 41.9 % | 0.3% | 26 | 141 | 62 |
| Barrett esophagus cancer | 12.5 % | 7% | 2 | 16 | 62 |
| Bipolar Disorder | 33.3 % | 3% | 11 | 33 | 62 |
| Asthma | 29.6 % | 8% | 8 | 27 | 62 |
| Atherosclerosis | 43.5 % | 50% | 27 | 524 | 62 |
| Acne | 42.1 % | 47% | 8 | 19 | 62 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 43.8 % | 52% | 7 | 16 | 62 |
| Generalized anxiety disorder | 21.4 % | 2.7% | 3 | 14 | 62 |
| Brain Trauma | 45.5 % | 0.367% | 10 | 22 | 62 |
| Sjögren syndrome | 24.4 % | 1.2% | 10 | 41 | 62 |
| Type 2 Diabetes | 50 % | 10.8% | 31 | 267 | 62 |
| Stress / posttraumatic stress disorder | 23.2 % | 5.2% | 13 | 56 | 62 |
| ADHD | 23.4 % | 9.4% | 11 | 47 | 62 |
| Hashimoto's thyroiditis | 21.4 % | 0.35% | 3 | 14 | 62 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.